Lloyd Tillman

US Patent:

7576067, Aug 18, 2009

Filed:

Dec 1, 2004

Appl. No.:

11/000814

Inventors:

Susan Weinbach - San Diego CA, US
Lloyd G. Tillman - Oceanside CA, US
Richard S. Geary - Carlsbad CA, US
Gregory E. Hardee - Carlsbad CA, US

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 31/70
A61K 31/20
A61K 9/22
A61K 9/52
C07H 21/04

US Classification:

514 44, 514558, 536 245, 424468, 424494

Abstract:

Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a penetration enhancer which are released at a first location in the intestine, and a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix. This penetration enhancer is released at a second location in the intestine downstream from the first location and enhances absorption of the drug when it reaches the second location.

US Patent:

20030027780, Feb 6, 2003

Filed:

Feb 8, 2002

Appl. No.:

10/071822

Inventors:

Gregory Hardee - Rancho Santa Fe CA, US
Lloyd Tillman - Carlsbad CA, US
Maria Gonzalez-Ferreiro - Berlin, DE
Rahul Mehta - San Marcos CA, US
Ching-Leou Teng - San Diego CA, US

International Classification:

A61K048/00
A61K009/14

US Classification:

514/044000, 424/046000

Abstract:

The present invention is related to non-parenteral multiparticulate formulations capable of transporting therapeutic, prophylactic and diagnostic agents across mucosal membranes such as gastrointestinal, buccal, nasal, rectal and vaginal. Formulations comprise a plurality of carrier particles, an agent to be delivered across a mucosal membrane, and a penetration enhancer. The drug is adhered to the surface of the carrier particle or is impregnated within by electrostatic, covalent or mechanical forces.

US Patent:

20040229831, Nov 18, 2004

Filed:

Mar 4, 2004

Appl. No.:

10/793497

Inventors:

Ching-Leou Teng - San Diego CA, US
Phillip Cook - Fallbrook CA, US
Lloyd Tillman - Oceanside CA, US
Gregory Hardee - Rancho Sante Fe CA, US
David Ecker - Encinitas CA, US
Muthiah Manoharan - Weston MA, US

Assignee:

ISIS Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K048/00
A61L009/04

US Classification:

514/044000, 424/045000

Abstract:

The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes. The compositions and methods of the invention are utilized to effect the oral, buccal, rectal or vaginal administration of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic, palliative or prophylactic purposes.

US Patent:

20130274309, Oct 17, 2013

Filed:

Jan 7, 2013

Appl. No.:

13/735229

Inventors:

Isis Pharmaceuticals, Inc. - , US
Phillip Dan Cook - Cardiff CA, US
Lloyd Tillman - Encinitas CA, US
Gregory E. Hardee - Del Mar CA, US
David J. Ecker - Encinitas CA, US
Muthiah Manoharan - Weston MA, US

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 48/00

US Classification:

514 44 A

Abstract:

The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes. The compositions and methods of the invention are utilized to effect the oral, buccal, rectal or vaginal administration of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic, palliative or prophylactic purposes

US Patent:

20210079391, Mar 18, 2021

Filed:

Jun 9, 2020

Appl. No.:

16/896752

Inventors:

- Carlsbad CA, US
Lloyd Tillman - Encinitas CA, US
Bret Coldren - Vista CA, US
Marc Lim - Fullerton CA, US

International Classification:

C12N 15/113
C12N 15/11
A61K 31/7115
A61K 31/712
A61K 31/7125

Abstract:

The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.

US Patent:

20190316123, Oct 17, 2019

Filed:

Nov 28, 2018

Appl. No.:

16/203156

Inventors:

- Carlsbad CA, US
Lloyd Tillman - Encinitas CA, US
Bret Coldren - Vista CA, US
Marc Lim - Fullerton CA, US

Assignee:

Ionis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C12N 15/113
C12N 15/11

Abstract:

The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.

US Patent:

20170211062, Jul 27, 2017

Filed:

Oct 14, 2016

Appl. No.:

15/293613

Inventors:

- Carlsbad CA, US
Lloyd Tillman - Encinitas CA, US
Bret Coldren - Vista CA, US
Marc Lim - Fullerton CA, US

Assignee:

Ionis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C12N 15/113

Abstract:

The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.

US Patent:

20160002624, Jan 7, 2016

Filed:

May 17, 2013

Appl. No.:

14/401761

Inventors:

- Carlsbad CA, US
Lloyd Tillman - Encinitas CA, US
Bret Coldren - Vista CA, US
Marc Lim - Oceanside CA, US

Assignee:

ISIS PHARMACEUTICALS, INC. - Carlsbad CA

International Classification:

C12N 15/113

Abstract:

The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.